



HHS PUBLIC ACCESS

Author manuscript

Curr Opin Infect Dis. Author manuscript; available in PMC 2017 October 01.

Published in final edited form as:

Curr Opin Infect Dis. 2016 October ; 29(5): 502–507. doi:10.1097/QCO.0000000000000293.

Giardia: a pathogen or commensal for children in high prevalence settings?

Luther A. Bartelt^a and James A. Platts-Mills^b^aDivision of Infectious Diseases, University of North Carolina at Chapel Hill, 130 Mason Farm Road, Chapel Hill, NC 27599-7030, Phone: (919) 966-6152^bDivision of Infectious Diseases and International Health, University of Virginia Health System, P.O. Box 801340, Charlottesville, VA 22908, Phone: (434) 243-8997, Fax: (434) 924-0075

Abstract

Purpose of review—*Giardia* is a common intestinal parasite worldwide, and infection can be associated with clear and sometimes persistent symptomatology. However, in children in high prevalence settings, it is not associated with or is perhaps even protective against acute diarrhea, and the association with long-term outcomes has been difficult to discern.

Recent findings—Recent studies have made progress in helping us disentangle this apparent paradox. First, prospective, well-characterized cohort studies have added to the data on the association between *Giardia* and diarrhea in these settings and have further characterized associations between *Giardia* infection and nutrition, gut function, and growth. Second, animal models have further characterized the host response to *Giardia* and helped elucidate mechanisms by which *Giardia* could impair child development. Finally, new work has shed light on the heterogeneity of human *Giardia* strains, which may both explain discrepant findings in the literature and help guide higher-resolution analyses of this pathogen in the future.

Summary—The true clinical impact of endemic pediatric giardiasis remains unclear, but recent prospective studies have confirmed a high prevalence of persistent, subclinical *Giardia* infections and associated growth shortfalls. Integrating how nutritional, microbial, metabolic, and pathogen-strain variables influence these outcomes could sharpen delineations between pathogenic and potentially beneficial attributes of this enigmatic parasite.

Keywords

Giardia; diarrhea; child growth; child development; environmental enteropathy

INTRODUCTION: WHENCE THE BLACK BOX?

Giardia lamblia (also known as *G. intestinalis/duodenalis*) is one of the most common intestinal parasitic infections in both children and adults worldwide. Giardiasis has a clear

Correspondence to: James A. Platts-Mills.**Conflicts of interest**

There are no conflicts of interest.

case definition characterized by malabsorptive diarrhea, abdominal bloating/cramping, and weight loss [1] that is reproducible, if strain-dependent, in human volunteers [2] and resolves with treatment. Infection can lead to intestinal inflammation [3], systemic cellular immunity [4], and lingering symptoms, even for several years [5]. *Giardia* has also been implicated as a cause of diarrhea in travelers from non-endemic to endemic countries [6], with the greatest risk amongst backpackers in Asia [7]. Children living in limited-resource settings, many of whom are undernourished, harbor a particularly large burden of *Giardia* infection.

However, recent assessments of pathogen-specific diarrhea in such settings find no *Giardia*-attributable burden of diarrhea in this population [8, 9*]. Indeed, the finding in several studies that *Giardia* infection is associated with a decreased likelihood of acute diarrhea [6, 10, 11] has fostered speculation that such colonization is not only inconsequential, but even protective in these children. Thus, despite its high prevalence in this vulnerable population, *Giardia*, unlike other enteropathogens (e.g., *Campylobacter* or *Cryptosporidium*) is completely absent from global burden of disease estimates [12]. Here we review recent work that addresses this epidemiological conundrum that seemingly categorizes *Giardia* simultaneously as both harmful pathogen and intestinal commensal.

DOES *GIARDIA* CAUSE ACUTE DIARRHEA IN HIGH-PREVALENCE SETTINGS?

The recently-completed Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development Project (MAL-ED) allows for the most comprehensive analysis of *Giardia* infection in these settings to date. Over the period of November 2009 to February 2014, *Giardia* was detected in two-thirds of 1,741 children completing the study through 2 years of age, with wide variation in median time to first detection among the eight study sites [13]. *Giardia* was detected in 37 to 95% of children at each site within the first two years of life and persistent infection was common. However, when adjusting for *Giardia* detection in non-diarrheal stools and the presence of co-pathogens, *Giardia* was not significantly associated with diarrhea, regardless of site or child age [9*]. In other work, *Giardia* was not an independent risk factor for diarrhea in children presenting to clinics after travel to sub-Saharan Africa, Latin America, and South Asia, even though it was among the most frequently detected pathogens in 10.1% of stools [14]. The strikingly high prevalence of non-diarrheal *Giardia* infections [6, 8, 9*, 15, 16**] is such that *Giardia* detection has frequently been negatively associated with diarrhea [6, 8, 17, 18]. Several factors could preferentially decrease the sensitivity of *Giardia* detection preferentially in diarrheal stools. First, metronidazole is commonly used as empiric therapy for diarrhea in these settings. Thus, diarrhea could be a marker of metronidazole exposure, which could reduce *Giardia* detection in diarrheal stools. Second, detection artifact due to a decreased sensitivity of microscopy-based detection in liquid stools might partially explain this phenomenon [18]. However, studies using antigen-based diagnostics that are presumably more resistant to such a dilutional effect have corroborated these findings [8], and quantitative nucleic-acid based diagnostics have also suggested that higher quantities of *Giardia* are associated with even greater reductions in diarrhea risk [17], an inversion of

Koch's molecular postulates and the opposite of what is seen with pathogens that are clearly diarrhea associated [17,19,20]. This suggestion of a protective effect of *Giardia* against diarrhea has primarily come from case-control studies, however prospective studies have also found evidence of such [10, 11]. These findings are not universal, and *Giardia* was not seen to be protective against diarrhea in a recent birth cohort study in Bangladesh [16**].

If real, what could explain this protective effect? The list of potential explanations is long, and data are few. Early *Giardia* infection may be an environmental marker of exposure to multiple enteropathogens. Thus, children with *Giardia* infection at baseline in longitudinal studies may be more likely to have already developed immunity to these pathogens and be less likely to have subsequent clinical diarrhea due to enteric infections. Second, *Giardia* may induce a specific micronutrient deficiency (e.g., iron) that is protective against diarrhea [21]. Intriguingly, in one prospective study, the protective effect of *Giardia* infection on acute diarrhea was not discerned in children who were randomized to receive micronutrient supplementation [11]. Thirdly, *Giardia* may more broadly modulate immune responses to other pathogens [22] or even directly bind enterotoxins [23]. Finally, unidentified environmental or host factors such as breastfeeding practices, genetics, or intestinal microbiota could differentially influence *Giardia* manifestations in young children. Further work is needed to understand the specificity and potential mechanisms driving this intriguing association.

IS *GIARDIA* INFECTION ASSOCIATED WITH POOR GROWTH?

Child growth, rather than incident diarrhea, might be a more relevant outcome for estimating the burden of endemic pediatric giardiasis. Historically, associations between *Giardia* and impairments in child growth have varied by study, population, and site, leaving unanswered questions regarding causal relationships between the parasite and child developmental sequelae. In MAL-ED, no consistent association was seen between a high burden of *Giardia* infection during the first two years of life and height attainment over that interval [24]. However, there was a strong association between persistent *Giardia* infection within the first six months of life and height attainment at 2 years (Rogawski ET, Bartelt LA, Platts-Mills JA, unpublished data). Similarly, in a single site birth cohort in Bangladesh where *Giardia* infection was nearly universal, with an average of 3.5 *Giardia* positive monthly surveillance stools per child in the first year of life, an impact on growth attainment at two years of age was seen in children with a first *Giardia* detection in the first six months of life [16**]. Since the majority of first *Giardia* exposures occur after one year of age, other factors such as total pathogen burden had a greater overall effect on childhood growth at two years of age [24]. These findings could suggest an early, critical window of childhood vulnerability which is seldom captured in a focused manner. However, it is also possible that the chronic consequences of *Giardia* persistence into the second year of life were not yet evident at the completion of follow-up. Additionally, ongoing exposures to deworming agents with anti-giardial activity such as mebendazole for soil-transmitted helminths which overlap with *Giardia* prevalence [25, 26] in older children could also interrupt *Giardia* persistence and abrogate the impact of *Giardia* on growth in older children.

WHAT IS THE PATHWAY BETWEEN *GIARDIA* INFECTION AND POOR GROWTH?

The current working model of enteropathogen-associated growth shortfalls in children links nutrient deficiencies with microbial-driven intestinal inflammation, gut dysfunction, and increased intestinal permeability, termed environmental enteropathy (EE)[27, 28**]. Chronic *Giardia* infection has been associated with altered intestinal architecture and chronic lymphocytic inflammation in humans and some experimental models [4, 29, 30]. In MAL-ED, *Giardia* infection was associated with an increased lactulose:mannitol (L:M) ratio, indicative of increased gut permeability, but fecal myeloperoxidase (MPO), a marker of neutrophil inflammation, was paradoxically lower in children with *Giardia*, and *Giardia* was not associated with increased fecal neopterin as a marker of T-cell activation or the acute phase reactant α -1-acid glycoprotein (Rogawski ET, Bartelt LA, Platts-Mills JA, unpublished data). Thus, while impaired gut function represents a putative pathway for poor growth during giardiasis, the mechanisms appear to be independent of both diarrhea and inflammation.

Recent laboratory work supports these findings and suggests new lines of investigation for understanding the association between *Giardia* and poor growth. First, both parasite-induced and host cellular- or cytokine-mediated alterations in tight junctions could participate in increased gut permeability during giardiasis. For example, direct contact between intestinal epithelial cell monolayers and some *Giardia* strains lead to degradation of cytoskeletal villin protein as well as the tight-junction protein zonula occludens 1 (ZO-1) [31*]. In an experimental model, *Giardia* degraded epithelial cell tight junction proteins occludin and claudin-4 [32*] and increased para-cellular translocation of intestinal bacteria. Inflammation, gut hypersensitivity, and evidence of ongoing bacterial translocation, were present well after parasite clearance, suggesting that *Giardia*-induced alterations in epithelial barrier may explain chronic intestinal sequelae following *Giardia* exposures [5, 33]. Finally, host immune responses during experimental *Giardia* infections also contribute to epithelial cell dysfunction and are entirely sufficient to cause microvillus alterations in the absence of the parasite [34].

Second, the absence of an association between *Giardia* and markers of inflammation in MAL-ED are consistent with the frequent lack of acute inflammation on histopathology during *Giardia* infection, decreased fecal neutrophil chemotactic markers such as IL-8 during more prolonged *Giardia* infections [35], and an association between *Giardia* and lower systemic C-reactive protein levels [11]. Indeed, *Giardia* contains an impressive repertoire of immunoevasive products [36*] that are upregulated upon sensing secreted host factors even prior to parasite attachment [37] and could have implications for modulating host responses to co-pathogens or resident microbiota. For example, cathepsin B-producing *Giardia* strains are capable of cleaving IL-8 and attenuating neutrophil chemotaxis to inflammatory stimuli [38, 39]. Interestingly, inhibition of cathepsin B prevents *Giardia*-induced epithelial cell villin protein degradation, potentially linking a single virulence factor that could lead to divergent gut permeability and inflammation findings [31*]. Translating

similar outcomes into children will require further elucidation of *Giardia* strain differences since this effect was restricted to specific laboratory isolates.

Third, both the finding that persistent *Giardia* infections have the greatest influence on childhood growth and the clear association between *Giardia* and persistent diarrhea [6] suggest that a subset of children fail to make an appropriate immune response. While host factors associated with clinical recurrent giardiasis have generally focused on secretory IgA, recall assays in travelers with giardiasis have identified IL-17A-producing CD4⁺ T-cells as the predominate memory cell phenotype [40*] in those who cleared parasites more rapidly, consistent with recent murine models invoking the role of Th17 cells in *Giardia* clearance [41]. The specific relevance of the Th17 axis during *Giardia* infection has not been elucidated, but since IL17 has been shown to enhance intestinal epithelial barrier function [42], determining whether children with persistent *Giardia* infection have impairments in IL17-mediated immunity and consequently barrier dysfunction even in the absence of increased inflammation may reveal additional mechanisms driving increased intestinal permeability in this population.

Finally, while growth is an important outcome for prospective studies of early child development, growth shortfalls remain a non-specific outcome for EE. Ongoing work into better non-invasive measures of EE may help also help resolve the relationship between *Giardia* and childhood growth via EE [26, 43, 44]. Recently identified regulators of β -oxidation and energy flux via nicotinamide metabolism may represent novel metabolic pathways driving childhood malnutrition [45*]. Children with *Giardia* infection excrete greater amounts of urinary lipid markers of oxidative damage and erythrocyte catalase, suggestive of chronic systemic oxidation [46*]. Experimental models are actively pursuing how persistent *Giardia* infection dysregulates gut microbial-host co-metabolic adaptations to the nutrient-deprivation condition. Ascertaining whether such changes are due to direct effects of *Giardia* or alternatively whether either microbial interactions or the immune modulation associated with *Giardia* infection influence the metabonome will be important to resolve.

GIARDIA BY ANY OTHER NAME...

G. lamblia is conventionally categorized into eight genotypically distinct assemblages, each with a restricted host range, with the majority of human *Giardia* infections due to assemblage A or B. Unlike the characteristics that distinguish the pathogenicity of some other enteric infections, no single marker ascribes virulence potential to clinical *Giardia* isolates. Despite clear differences in experimental models and in human volunteers, there remains no consistent delineation between assemblage infection type and symptoms [47]. An assemblage A human isolate strain (Human *Giardia* Invader, HGINV) was recently identified with mucosal invasive potential, but weight loss in an animal model was no greater than infection with a non-invasive and generally less virulent laboratory-passaged assemblage A strain [48*].

The two *Giardia* assemblages are genetically and phenotypically distinguishable [49], sharing less than 70% sequence identity across syntenic regions [50]. Within assemblage B

there is a consistently greater degree of genetic diversity than assemblage A [51, 52]. Additionally, there is ongoing population expansion of *Giardia* haplotype diversity across all continents [53]. Even within a single isolate, *Giardia* displays a high degree of allelic sequence heterozygosity [54]. Proteomics studies reveal that even within the less genetically heterogeneous assemblage A, specific differences in proteins correspond with variable gene families. Notably, differences in variant surface proteins among eight separate isolates aligned with two different profiles that were independent of host origin, sub-assemblage designation, or geographic region [55–57]. With an increasing reference database of different *Giardia* laboratory strains, use of optimized techniques to perform whole genome sequencing from clinical isolates may help identify strain-specific correlates of disease [58*, 59]. Applied to field studies, this additional resolution may help separate out the pathogenic signal from commensal noise.

CONCLUSION

In conclusion, *Giardia* has distinct population-dependent epidemiological patterns. The parasite can cause malabsorptive diarrhea as well as chronic intestinal sequelae when exposures are infrequent and occur later in life, but is at once seemingly inconsequential or even beneficial for diarrhea incidence while contributing to impaired intestinal permeability and growth attainment when infection occurs in early childhood and where exposures are frequent. To consider *Giardia* a commensal would therefore be inappropriate, however, a paucity of clearly defined factors to distinguish virulence strains limits our ability to confidently ascribe pathogenicity. In the meantime, the direct influence of host-immune, nutritional, and microbial factors on experimental giardiasis outcomes may better classify *Giardia* as a eukaryotic pathobiont in high-prevalence settings with varied pathogenic potential across unique isolates and which commonly exists symbiotically but behaves opportunistically when genetic and environmental perturbations allow. As such, defining and addressing the elusive burden of one of the most common intestinal parasitic infections in humans may require broad thinking about complex microbial-host interactions, and careful examination and characterization of long-term sequelae.

Acknowledgments

LAB is supported by National Institutes of Health grant K08AI108730. JPM is supported by NIH grant K23AI114888. We gratefully acknowledge Elizabeth Rogawski, Pascal Bessong, and the MAL-ED network investigators for their contributions and insights.

REFERENCES AND RECOMMENDED READING

(**highly recommended -- *recommended – references with*s will need annotation)

1. Painter JE, Gargano JW, Collier SA, et al. Giardiasis surveillance -- United States, 2011–2012. *MMWR Suppl.* 2015; 64:15–25. [PubMed: 25928582]
2. Nash TE, Herrington DA, Losonsky GA, Levine MM. Experimental human infections with *Giardia lamblia*. *J Infect Dis.* 1987; 156:974–984. [PubMed: 3680997]
3. Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to *Giardia duodenalis* infection. *J Infect.* 2007; 55:524–530. [PubMed: 17964658]
4. Hanevik K, Kristoffersen E, Svard S, et al. Human cellular immune response against *Giardia lamblia* 5 years after acute giardiasis. *J Infect Dis.* 2011; 204:1779–1786. [PubMed: 21990423]

5. Hanevik K, Wensaas KA, Rortveit G, et al. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. *Clin Infect Dis*. 2014; 59:1394–1400. [PubMed: 25115874]
6. Muhsen K, Levine MM. A systematic review and meta-analysis of the association between *Giardia lamblia* and endemic pediatric diarrhea in developing countries. *Clin Infect Dis*. 2012; 55(Suppl 4):S271–S293. [PubMed: 23169940]
7. Herbinger KH, Alberer M, Berens-Riha N, et al. Spectrum of imported infectious diseases: a comparative prevalence study of 16,817 German travelers and 977 Immigrants from the tropics and subtropics. *Am J Trop Med Hyg*. 2016; 94:757–766. [PubMed: 26903611]
8. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet*. 2013; 382:209–222. [PubMed: 23680352]
9. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). *Lancet Glob Health*. 2015; 3:e564–e575. [PubMed: 26202075] This study estimated pathogen-specific burdens of diarrhea from a community-based, multisite birth cohort study across three continents and consistent with GEMS, did not identify an burden of diarrhea attributable to *Giardia*, even for the subset of prolonged diarrhea.
10. Muhsen K, Cohen D, Levine MM. Can *Giardia lamblia* infection lower the risk of acute diarrhea among preschool children? *J Trop Pediatr*. 2014; 60:99–103. [PubMed: 24158113]
11. Veenemans J, Mank T, Ottenhof M, et al. Protection against diarrhea associated with *Giardia intestinalis* is lost with multi-nutrient supplementation: a study in Tanzanian children. *PLoS Negl Trop Dis*. 2011; 5:e1158. [PubMed: 21666789]
12. 2013 GBD Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015; 385:117–171. [PubMed: 25530442]
13. MAL-ED Network Investigators. The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. *Clin Infect Dis*. 2014; 59:S193–S206. [PubMed: 25305287]
14. Soriano-Arandes A, Garcia-Carrasco E, Serre-Delcor N, et al. Travelers' diarrhea in children at risk: an observational study from a Spanish database. *Ped Infect Dis J*. 2016; 35:392–395.
15. Tellevik MG, Moyo SJ, Blomberg B, et al. Prevalence of *Cryptosporidium parvum/hominis*, *Entamoeba histolytica* and *Giardia lamblia* among young children with and without diarrhea in Dar es Salaam, Tanzania. *PLoS Negl Trop Dis*. 2015; 9:e0004125. [PubMed: 26452235]
16. Donowitz J, Alam M, Kabir M, et al. A prospective longitudinal cohort to investigate the effects of early life giardiasis on growth and all cause diarrhea. *Clin Infect Dis*. 2016 Jun 16. [Epub ahead of print]. This major study followed 629 children in Bangladesh from birth through two years of life *Giardia* cumulative incidence by two years of life was 74%, and a *Giardia* positive stool in the first 6 months of life was associated with lower height attainment at age two (decreased length-for-age Z score by 0.40 (95% confidence interval (CI): –0.80 to –0.00).
17. Liu J, Kabir F, Manneh J, et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. *Lancet Infect Dis*. 2014; 14:716–724. [PubMed: 25022434]
18. Breurec S, Vanel N, Bata P, et al. Etiology and epidemiology of diarrhea in hospitalized children from low income country: a matched case-control study in Central African Republic. *PLoS Negl Trop Dis*. 2016; 10:e0004283. [PubMed: 26731629]
19. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. *Clin Microbiol Rev*. 1996; 9:18–33. [PubMed: 8665474]
20. Platts-Mills JA, Liu J, Hout ER. New concepts in diagnostics for infectious diarrhea. *Mucosal Immunol*. 2013; 6:876–885. [PubMed: 23881355]

21. Hussein EM, Zaki WM, Ahmed SA, et al. Predominance of *Giardia lamblia* assemblage A among iron deficiency anaemic pre-school Egyptian children. *Parasitol Res.* 2016; 115:1537–1545. [PubMed: 26758448]
22. Roxstrom-Lindquist K, Palm D, Reiner D, et al. *Giardia* immunity--an update. *Trends Parasitol.* 2006; 22:26–31. [PubMed: 16303332]
23. McCardell BA, Madden JM, Stanfield JT, et al. Binding of cholera toxin to *Giardia lamblia*. *J Clin Microbiol.* 1987; 25:1786–1788. [PubMed: 3116038]
24. Caulfield, L. Factors affecting growth velocity and risk factors for stunting in the first 24 months of life. 64th Annual Meeting of the American Society of Tropical Medicine and Hygiene; October, 2015; Philadelphia, PA.
25. Ferreira FS, Baptista-Fernandes T, Oliveira D, et al. *Giardia duodenalis* and soil-transmitted helminths infections in children in Sao Tome and Principe: do we think *Giardia* when addressing parasite control? *J Trop Pediatr.* 2015; 61:106–112. [PubMed: 25604490]
26. Cimino RO, Jeun R, Juarez M, et al. Identification of human intestinal parasites affecting an asymptomatic peri-urban Argentinian population using multi-parallel quantitative real-time polymerase chain reaction. *Parasites Vectors.* 2015; 8:380. [PubMed: 26183074]
27. Kosek M, Guerrant RL, Kang G, et al. Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework. *Clin Infect Dis.* 2014; 59:S239–S247. [PubMed: 25305293]
27. Yu J, Ordiz MI, Stauber J, et al. Environmental enteric dysfunction includes a broad spectrum of inflammatory responses and epithelial repair processes. *Cell Mol Gastroenterol Hepatol.* 2016; 2:158–174. e1. [PubMed: 26973864] This study exemplifies innovative approaches to determining putative pathways of childhood growth impairment and gut dysfunction. The study isolated host transcriptomics in fecal specimens from 229 children with biochemical evidence of impaired intestinal permeability ranging from none to severe. Children with indicators of both impaired intestinal permeability and diminished height attainment expressed more transcripts mapping to broad immune activation and cell adhesion, but fewer transcripts related to mucus production and maintenance.
29. Bartelt LA, Roche J, Kolling G, et al. Persistent *G. lamblia* impairs growth in a murine malnutrition model. *J Clin Invest.* 2013; 123:2672–2684. [PubMed: 23728173]
30. Troeger H, Epple HJ, Schneider T, et al. Effect of chronic *Giardia lamblia* infection on epithelial transport and barrier function in human duodenum. *Gut.* 2007; 56:328–335. [PubMed: 16935925]
31. Bhargava A, Cotton JA, Dixon BR, et al. *Giardia duodenalis* surface cysteine proteases induce cleavage of the intestinal epithelial cytoskeletal protein Villin via myosin light chain kinase. *PLoS One.* 2015; 10:e0136102. [PubMed: 26334299] This study found that villin degradation was both contact-dependent and resulted from *Giardia* strain-dependent increases in cathepsin cysteine proteases.
32. Halliez MC, Motta JP, Feener TD, et al. *Giardia duodenalis* induces para-cellular bacterial translocation and causes post-infectious visceral hypersensitivity. *Am J Physiol Gastrointest Liver Physiol.* 2016 ajpgi 00144 2015. This new model of post-*Giardia* sequelae identified ongoing intestinal tight junction disruption together with increased mucosal bacterial translocation that persisted well beyond parasite clearance.
33. Litleskare S, Wensaas KA, Eide GE, et al. Perceived food intolerance and irritable bowel syndrome in a population 3 years after a giardiasis-outbreak: a historical cohort study. *BMC Gastroenterol.* 2015; 15
34. Bartelt LA, Sartor RB. Advances in understanding *Giardia*: determinants and mechanisms of chronic sequelae. *F1000Prime Rep.* 2015; 7:62. [PubMed: 26097735]
35. Long KZ, Rosado JL, Santos JI, et al. Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. *Infect Immun.* 2010; 78:1221–1228. [PubMed: 20038536]
36. Cotton JA, Amat CB, Buret AG. Disruptions of host immunity and inflammation by *Giardia duodenalis*: potential consequences for co-infections in the gastro-intestinal tract. *Pathogens.* 2015; 4:764–792. [PubMed: 26569316] This comprehensive review examines putative mechanisms whereby *Giardia* may influence co-enteropathogen infections in children through modulation of mucosal immune responses.

37. Emery SJ, Mirzaei M, Vuong D, et al. Induction of virulence factors in *Giardia duodenalis* independent of host attachment. *Sci Rep.* 2016; 6:20765. [PubMed: 26867958]
38. Cotton JA, Bhargava A, Ferraz JG, et al. *Giardia duodenalis* cathepsin B proteases degrade intestinal epithelial interleukin-8 and attenuate interleukin-8-induced neutrophil chemotaxis. *Infect Immun.* 2014; 82:2772–2787. [PubMed: 24733096]
39. Cotton JA, Motta JP, Schenck LP, Hirota SA, Beck PL, Buret AG. *Giardia duodenalis* infection reduces granulocyte infiltration in an in vivo model of bacterial toxin-induced colitis and attenuates inflammation in human intestinal tissue. *PLoS One.* 2014; 9:e109087. [PubMed: 25289678]
40. Saghaug CS, Sornes S, Peirasmaki D, et al. Human Memory CD4+ T Cell Immune Responses against *Giardia lamblia*. *CVI.* 2015; 23:11–18. [PubMed: 26376930] This is the first study to examine the relative importance of specific cytokines in memory responses to *Giardia* infection in human subjects. Though the sample size was small, the findings that IL-17A producing memory CD4+ T-cells predominated responses, and greater IL-17A production was associated with a short duration of infection, opens important future avenues in understanding immunity to *Giardia*.
41. Dann SM, Manthey CF, Le C, et al. IL-17A promotes protective IgA responses and expression of other potential effectors against the lumen-dwelling enteric parasite *Giardia*. *Exp Parasitol.* 2015; 156:68–78. [PubMed: 26071205]
42. Lee Jacob S, Tato Cristina M, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. *Immunity.* 2015; 43:1022.
43. McDonald CM, Manji KP, Gosselin K, et al. Elevations in serum anti-flagellin and anti-LPS Igs are related to growth faltering in young Tanzanian children. *Am J Clin Nutr.* 2016 April 27 [Epub ahead of print].
44. Kosek M, Haque R, Lima A, et al. Fecal markers of intestinal permeability associated with the subsequent acquisition of linear growth deficits in infants. *Am J Trop Med Hyg.* 2013; 68:390–396.
45. Mayneris-Perxachs J, Lima AA, Guerrant RL, et al. Urinary N-methylnicotinamide and beta-aminoisobutyric acid predict catch-up growth in undernourished Brazilian children. *Sci Rep.* 2016; 6:19780. [PubMed: 26816084] This study is the first to demonstrate the ability of urinary metabolomics to predict growth in undernourished children and identifies potentially novel and more easily accessible markers of intestinal dysfunction.
46. Soto-Mendez MJ, Aguilera CM, Mesa MD, et al. Interaction of *Giardia intestinalis* and systemic oxidation in preschool children in the western highlands of Guatemala. *J Pediatr Gastroenterol Nutr.* 2015 Jun 23 [Epub ahead of print]. This was another study that use urinary markers in a population with a high prevalence of malnutrition. Their findings of increased markers of oxidative stress raise new potential metabolic pathways whereby *Giardia* contributes to impaired growth attainment.
47. Choy SH, Al-Mekhlafi HM, Mahdy MA, et al. Prevalence and associated risk factors of *Giardia* infection among indigenous communities in rural Malaysia. *Sci Rep.* 2014; 4:6909. [PubMed: 25366301]
48. Reynoso-Robles R, Ponce-Macotela M, Rosas-Lopez LE, et al. The invasive potential of *Giardia intestinalis* in an in vivo model. *Sci Rep.* 2015; 5:15168. [PubMed: 26470844] This group reports the first evidence of an original human *Giardia* isolate that demonstrated evidence of mucosal invasion in both an infected patient and in a rodent model. This finding raises the importance of confirming invasive potential with other isolates and in other models.
49. Franzén O, Jerlström-Hultqvist J, Castro E, et al. Draft genome sequencing of *Giardia intestinalis* assemblage B isolate GS: is human giardiasis caused by two different species? *PLoS Pathog.* 2009; 5:e1000560. [PubMed: 19696920]
50. Adam RD, Dahlstrom EW, Martens CA, et al. Genome sequencing of *Giardia lamblia* genotypes A2 and B isolates (DH and GS) and comparative analysis with the genomes of genotypes A1 and E (WB and Pig). *Genome Biol Evol.* 2013; 5:2498–2511. [PubMed: 24307482]
51. De Lucio A, Martinez-Ruiz R, Merino FJ, et al. Molecular genotyping of *Giardia duodenalis* isolates from symptomatic individuals attending two major public hospitals in Madrid, Spain. *PLoS One.* 2015; 10:e0143981. [PubMed: 26641082]

52. Soba B, Islamovic S, Skvarc M, Caccio SM. Multilocus genotyping of *Giardia duodenalis* (Lambl, 1859) from symptomatic human infections in Slovenia. *Folia Parasitol.* 2015; 62
53. Choy SH, Mahdy MAK, Al-Mekhlafi HM, et al. Population expansion and gene flow in *Giardia duodenalis* as revealed by triosephosphate isomerase gene. *Parasite Vectors.* 2015; 8:1–10.
54. Ankarklev J, Franzen O, Peirasmaki D, et al. Comparative genomic analyses of freshly isolated *Giardia intestinalis* assemblage A isolates. *BMC Genomics.* 2015; 16(1):697. [PubMed: 26370391]
55. Emery SJ, Lacey E, Haynes PA. Data from a proteomic baseline study of Assemblage A in *Giardia duodenalis*. *Data in Brief.* 2015; 5:23–27. [PubMed: 26380841]
56. Emery SJ, Lacey E, Haynes PA. Quantitative proteomic analysis of *Giardia duodenalis* assemblage A: A baseline for host, assemblage, and isolate variation. *Proteomics.* 2015; 15:2281–2285. [PubMed: 25728068]
57. Wielinga C, Thompson RC, Monis P, Ryan U. Identification of polymorphic genes for use in assemblage B genotyping assays through comparative genomics of multiple assemblage B *Giardia duodenalis* isolates. *Mol Biochem Parasitol.* 2015; 201:1–4. [PubMed: 26003141]
58. Aguiar JM, Silva SO, Santos VA, et al. Multilocus amplification of genomic DNA from single cysts of *Giardia duodenalis* separated using micromanipulation technique. *Exp parasitol.* 2015; 157:84–87. [PubMed: 26172406] These investigators demonstrate the ability to isolate a single *Giardia* cyst, opening the door for higher precision comparative genomics studies
59. Hanevik K, Bakken R, Brattbakk HR, et al. Whole genome sequencing of clinical isolates of *Giardia lamblia*. *Clinical Microbiol Infect.* 2015; 21:192, e1–e3. [PubMed: 25596782]

KEY POINTS

- New field studies have helped characterize associations between *Giardia* and both diarrhea and growth in children living in high prevalence settings.
- Recent work in *Giardia* pathogenesis is helping reconcile possible mechanisms through which *Giardia* could protect against acute diarrhea, but simultaneously impair growth attainment in these children.
- Advances in comparative genomics may identify novel characteristics that better identify pathogenic *Giardia* strains, which in turn could help refine burden of disease estimates for this complex organism.